This announcement is a separate document:
Enel Chile | 6-K: Report of foreign private issuer (related to financial reporting)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
19:31
The China Securities Regulatory Commission issued the "Guidelines on Regulatory Rules - Institutions Class No. 4" to further strengthen the professional competencies of the Chairman and General Manager of securities and Fund operation institutions. Candidates for the positions of Chairman and General Manager should have at least 3 years of experience in securities, funds, or financial work, and at least one person must have more than 3 years of relevant experience in securities or Fund operations. This requirement applies to individuals nominated for the positions of Chairman and General Manager after the issuance of these guidelines.
19:31
The Securities Regulatory Commission issued a notice for the "full circulation" filing of Yaokai Ankang's overseas issuance and listing and the unlisted shares in the domestic market.
19:30
Novo-Nordisk A/S spokesperson: Complete results of Cagrisema will be announced at next year's medical conference. We plan to optimize dosage adjustments and further explore Cagrisem as an additional weight loss potential, with plans to start a new trial in the first half of 2025.
NVO-2.38%